# A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

> **NCT01882803** · PHASE2 · COMPLETED · sponsor: **SecuraBio** · enrollment: 129 (actual)

## Conditions studied

- Indolent Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Duvelisib

## Key facts

- **NCT ID:** NCT01882803
- **Lead sponsor:** SecuraBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-17
- **Primary completion:** 2020-11-18
- **Final completion:** 2020-11-18
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2023-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01882803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01882803, "A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01882803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*